Novartis Expands Its Legal Fight on Entresto, Adding New Patent

Novartis said generic versions of Entresto proposed by Alkem, Aurobindo, Dr. Reddy’s, Hetero, Laurus, Macleods and Torrent infringe a patent issued last month and related to the blockbuster treatment for heart failure, expanding its courtroom offensive.

• Novartis is seeking cash compensation and court order blocking copies until patent has expired, according to complaint filed Monday in federal court in Wilmington, Delaware
• Patent was issued Aug. 24 and covers an “amorphous solid form of a compound comprising anionic valsartan, anionic sacubitril, and sodium cations in a 1:1:3 molar ratio,” complaint says
  • Patent expires in November 2026: ...